Fiera Capital Corp Has $38.12 Million Stake in AbbVie Inc. $ABBV
Fiera Capital Corp increased its stake in AbbVie Inc. (NYSE:ABBV) by 51.3% in Q3, bringing its total holdings to $38.12 million. Several other institutional investors also adjusted their positions in the pharmaceutical company. Key news impacting AbbVie includes FDA approval for a VENCLEXTA® and acalabrutinib combination for CLL, new Phase 2a study for ABBV-142, and a declared quarterly dividend of $1.73.
Absci Advances Lead AI-Designed Candidate for IBD into the Clinic
Absci has advanced its lead AI-designed candidate, ABS-101, for inflammatory bowel disease (IBD) into clinical trials. The company reported dosing the first healthy volunteers in a Phase I trial targeting tumor necrosis factor-like cytokine 1A (TL1A) and expects interim data in the second half of this year. Absci claims its AI platform significantly accelerated drug development, bringing ABS-101 to the clinic in just over 24 months for approximately $15 million, dramatically reducing both time and cost compared to traditional methods.
Botulinum Toxins Market Size & Growth Forecast to 2030
The global botulinum toxins market is projected to reach USD 15.72 billion by 2030, growing at a CAGR of 12.0% from USD 8.92 billion in 2025, driven by increasing aesthetic consciousness and expanding therapeutic applications. Key players include AbbVie, Ipsen, and Galderma, with significant market share in North America, while the Asia Pacific region is expected to show the highest growth. The market is influenced by a shift towards minimally invasive procedures, biosimilar competition, and product innovation.
AbbVie Inc. SEC 10-K Report
AbbVie Inc. has released its 2025 Form 10-K report, detailing robust financial performance, significant business achievements, and strategic initiatives. The report highlights strong net revenues and operating earnings, driven by growth in immunology products like Skyrizi and Rinvoq, despite competition for Humira. AbbVie also outlined new product launches, production expansions, and a commitment to R&D, while acknowledging challenges such as patent expirations, regulatory pressures, and supply chain risks.
Collagen Fillers Market Size, Share | Industry Report [2034]
The global collagen fillers market, valued at USD 49.87 million in 2025, is projected to reach USD 89.54 million by 2034, exhibiting a CAGR of 6.51%. This growth is driven by increasing demand for aesthetic procedures, advancements in biomaterials, and a surge in aesthetic clinics, particularly in the Asia Pacific region which dominated the market in 2025. Key factors influencing the market include the rising demand for collagen fillers in developing countries, competition from alternative products like hyaluronic acid fillers, and stringent regulatory landscapes.
Woodley Farra Manion Portfolio Management Inc. Buys 11,527 Shares of AbbVie Inc. $ABBV
Woodley Farra Manion Portfolio Management Inc. significantly increased its stake in AbbVie Inc. by 358.1% in Q3, purchasing an additional 11,527 shares to bring its total to 14,746 shares valued at $3.414 million. This move is part of broader institutional interest, with other large investors like Norges Bank and Vanguard also holding substantial positions. AbbVie recently reported strong financial results, including an EPS and revenue beat, and declared a quarterly dividend, while also receiving FDA approval for a new VENCLEXTA+acalabrutinib combination treatment for CLL.
Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
This article compares Ironwood Pharmaceuticals (IRWD) and Bausch Health (BHC) as investment options in the GI drug market. It highlights Ironwood's reliance on Linzess and its promising pipeline drug apraglutide, coupled with strong growth projections, despite its higher valuation. Bausch Health, while more diversified, faces challenges from high debt and recent pipeline setbacks, making Ironwood the preferred pick for investors due to its clearer growth trajectory.
Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more
This week saw increased dividend payouts from Sherwin-Williams and Analog Devices, alongside declarations from companies like Halliburton and AbbVie. Next week, major industry players such as Johnson & Johnson are also expected to make dividend declarations. The article highlights key dividend activities and upcoming announcements from various companies.
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
AbbVie reports strong growth driven by its newer immunology drugs, Skyrizi and Rinvoq, which are successfully offsetting the revenue decline of Humira. The company projects combined sales for these two drugs to exceed $31 billion by 2026 as they gain market share and expand into new therapeutic indications.
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
The FDA has approved a combination treatment from AbbVie and AstraZeneca for chronic lymphocytic leukemia (CLL), which could significantly improve patient outcomes by offering an all-oral, fixed-duration option. The approval is based on positive Phase 3 trial results showing the treatment's superiority over standard chemotherapy in delaying disease progression. Despite the positive news, AbbVie's stock performance lags slightly behind the broader healthcare sector, though analysts maintain a "Buy" rating.
Barclays initiates Abbvie stock with overweight on leverage potential
Barclays has initiated coverage on Abbvie Inc. (NYSE:ABBV) with an overweight rating and a price target of $275.00, citing the company's potential for operating leverage which they believe the market is underestimating. Despite the stock appearing overvalued according to InvestingPro data, Barclays expects successful outcomes from planned proof-of-concept studies in 2026 to drive multiple expansion. This comes after AbbVie reported strong Q4 2025 earnings, declared a dividend increase, and received an upgrade to A2 from Moody’s.
Manulife (NYSE: MFC) cleared to repurchase up to 42M shares
Manulife Financial Corporation has received Toronto Stock Exchange approval for a normal course issuer bid to repurchase and cancel up to 42 million common shares, approximately 2.5% of its outstanding stock. The buyback program is scheduled to run from February 24, 2026, to February 23, 2027, as part of the company's capital management strategy to enhance shareholder value.
AbbVie wins FDA approval for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia
AbbVie announced that the FDA has approved its Venclexta (venetoclax) and acalabrutinib combination regimen for the treatment of previously untreated adults with chronic lymphocytic leukemia (CLL). This approval expands the therapeutic options for patients battling this type of blood cancer in the first-line setting.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Stock Holdings in AbbVie Inc. $ABBV
BNP PARIBAS ASSET MANAGEMENT Holding S.A. significantly increased its stake in AbbVie Inc. by 44.1% during the third quarter, now owning 487,025 shares valued at over $111 million. Other institutional investors also adjusted their positions in the pharmaceutical company. Analyst ratings show a consensus of "Moderate Buy" for AbbVie, with recent price target adjustments reflecting varied projections for the stock.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The fill finish manufacturing market is projected to grow from $11.96 billion in 2025 to $21.04 billion by 2030, driven by the increasing demand for advanced therapies, personalized medicine, and outsourcing to CMOs. Key trends include the adoption of automated lines, aseptic processing, and single-use consumables. North America currently holds the largest market share, with Asia-Pacific expected to be the fastest-growing region.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The fill-finish manufacturing market is experiencing significant growth, projected to reach over $21 billion by 2030, driven by increased demand for biopharmaceuticals, cell and gene therapies, and personalized medicine. Key market drivers include advancements in aseptic filling technologies, rising outsourcing to CMOs, and a stronger focus on regulatory compliance. Major players like Johnson & Johnson, AbbVie, and Thermo Fisher Scientific are leading the innovation in this sector, with Asia-Pacific expected to be the fastest-growing region.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The global fill-finish manufacturing market is projected to grow from $11.96 billion in 2025 to over $21 billion by 2030, driven by surge in demand for cell and gene therapies and biologics. Key industry trends include the adoption of automated fill-finish lines, aseptic processing solutions, and increased outsourcing to contract manufacturing organizations (CMOs).
FDA approves first all-oral, fixed-duration option for CLL
The FDA has approved AbbVie's VENCLEXTA (venetoclax) in combination with acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL). This approval establishes the first all-oral, fixed-duration treatment option for front-line CLL, providing patients and providers with a time-limited regimen. The approval is based on data from the Phase 3 AMPLIFY trial, which demonstrated the combination's superiority over chemoimmunotherapy.
AbbVie Inc. (NYSE:ABBV) Declares Quarterly Dividend of $1.73
AbbVie Inc. (NYSE:ABBV) has declared a quarterly dividend of $1.73 per share, payable on May 15th to shareholders of record on April 15th, representing a 3.1% yield. The company has a history of raising its dividend annually for 53 consecutive years and maintains a payout ratio of 49.5%. AbbVie recently beat quarterly EPS and revenue estimates and provided positive FY2026 guidance, though the stock saw a slight dip.
Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board
Artiva Biotherapeutics, Inc. (ARTV) has appointed Elaine Sorg, a veteran pharmaceutical executive with over 35 years of experience from companies like AbbVie and Eli Lilly, to its board as a Class I director. Her term runs until the 2028 annual shareholder meeting, and her compensation includes an annual cash retainer and time-vested stock options, aligning her interests with shareholders. Despite this positive governance move, Artiva's stock is rated Neutral by TipRanks' AI Analyst, Spark, due to collapsing revenue, persistent losses, escalating cash burn, and financing risk, though partially offset by strong technical momentum and a positive clinical trial update.
AbbVie Declares Quarterly Dividend
AbbVie Inc. has declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, to stockholders of record on April 15, 2026. Since its inception in 2013, the company has increased its dividend by over 330 percent and is part of the S&P Dividend Aristocrats Index. AbbVie focuses on developing innovative medicines and solutions across immunology, neuroscience, oncology, and aesthetics.
AbbVie Keeps Quarterly Dividend at $1.73 a Share, Payable May 15 to Shareholders of Record on April 15
AbbVie Inc. announced that it will maintain its quarterly dividend at $1.73 per share. The dividend is scheduled to be paid on May 15, 2026, to shareholders who are on record as of April 15, 2026. This news was published on February 19, 2026, at 11:33 am EST.
Evercore Notes AbbVie Inc.'s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited
Evercore ISI lowered its price target on AbbVie (ABBV) to $228 from $232, maintaining an Outperform rating, despite Tremfya gaining market share. The firm noted that while AbbVie's 2026 guidance and current consensus estimates are achievable, future earnings growth might be limited as buy-side projections have exceeded consensus. Concerns are also rising about AbbVie's growth trajectory post-2028 due to anticipated rival treatments, even though the company reported strong 2025 performance and expects significant revenue growth in 2026 from Skyrizi and Rinvoq.
Why AstraZeneca PLC (AZN) is One of the Best Immunotherapy Stocks to Buy According to Hedge Funds
AstraZeneca PLC (AZN) is highlighted as a top immunotherapy stock favored by hedge funds, despite a recent "Sell" rating from Deutsche Bank. The company announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma, showing significant improvements and no new safety concerns. AstraZeneca specializes in biopharmaceutical exploration, development, manufacturing, and commercialization, focusing on prescription medicines and novel immuno-oncology treatments.
AbbVie declares quarterly dividend of $1.73 per share
AbbVie Inc. has declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, to stockholders of record as of April 15, 2026. This translates to an annual payout of $6.92 per share, with a current yield of approximately 3.03%. The company, part of the S&P Dividend Aristocrats Index, has increased its dividend by over 330% since its founding in 2013, following strong financial results for Q4 2025 and a credit rating upgrade by Moody's Ratings.
AbbVie (ABBV) Maintains Quarterly Dividend of $1.73/Share
AbbVie Inc. (ABBV) will maintain its quarterly dividend at $1.73 per share, providing a forward yield of 3.04%. The pharmaceutical giant, with a market capitalization of $400.55 billion, continues to be a dominant player in healthcare, despite some financial health concerns such as declining margins and high leverage. The company's valuation metrics suggest it might be overvalued, though institutional ownership remains strong.
Ontario Teachers Pension Plan Board Purchases Shares of 235,747 AbbVie Inc. $ABBV
The Ontario Teachers Pension Plan Board recently acquired 235,747 shares of AbbVie Inc. (ABBV), valued at approximately $54.6 million, making it their 19th largest holding. This move is part of a broader institutional trend, with other major investors like Norges Bank and Vanguard Group also increasing their stakes in AbbVie. The company continues to show strong performance, beating Q4 earnings estimates and receiving a "Moderate Buy" consensus rating from analysts.
Cumberland Partners Ltd Acquires 19,130 Shares of AbbVie Inc. $ABBV
Cumberland Partners Ltd significantly increased its stake in AbbVie Inc. by 76.2% during the third quarter, acquiring an additional 19,130 shares to bring its total holdings to 44,232 shares valued at $10.241 million. This increase comes as AbbVie reported strong Q1 2026 earnings, beating analyst estimates with $2.71 EPS and $16.62 billion in revenue, and received a "Moderate Buy" consensus rating from analysts with a target price of $251.56. Other institutional investors also adjusted their positions in AbbVie, with hedge funds now owning 70.23% of the company's stock.
Hemenway Trust Co LLC Has $45.81 Million Holdings in Abbott Laboratories $ABT
Hemenway Trust Co LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 3.1% in the third quarter, bringing their total holdings to $45.81 million across 342,006 shares. Despite this reduction, Abbott Laboratories remains Hemenway's 7th largest holding, making up approximately 3.5% of their investment portfolio. The article also notes recent insider buying by Director Daniel J. Starks and provides an overview of other institutional investor activity, the company's financial performance, dividend increase, and current analyst ratings.
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
Artiva Biotherapeutics, a clinical-stage biotechnology company focused on cell therapies for autoimmune diseases and cancers, has appointed Elaine Sorg to its Board of Directors. Sorg brings over 35 years of executive leadership and commercial experience in the biopharmaceutical industry, including scaling companies and launching immunology therapies like HUMIRA and RINVOQ. Her expertise is expected to be invaluable as Artiva prepares to share clinical data for its AlloNK regimen in rheumatoid arthritis and engage the FDA for a registrational trial.
AbbVie Inc. $ABBV Position Raised by L & S Advisors Inc
L & S Advisors Inc. significantly increased its stake in AbbVie Inc. by 134.8% in the third quarter, bringing their total holdings to 42,857 shares worth $9.923 million. Other institutional investors like Norges Bank, Laurel Wealth Advisors, and Vanguard Group also made substantial additions to their positions. AbbVie exceeded Q3 earnings expectations with $2.71 EPS and $16.62 billion in revenue, also providing strong FY 2026 guidance, while analysts maintain a "Moderate Buy" consensus rating with an average target price of $251.56.
RNAi Therapeutics Market to hit US$ 8.80 Billion by 2033 | North
The global RNAi Therapeutics Market is projected to reach US$ 8.80 billion by 2033, growing from US$ 2.60 billion in 2024 at a CAGR of 14.6%. North America currently leads the market with a 40% share, driven by key biotech companies and high R&D investments. The market growth is fueled by advancements in gene-silencing technologies, product innovations, and strategic acquisitions, with a focus on treating rare and chronic conditions.
Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story
Teva Pharmaceutical Industries and Sanofi announced positive long-term phase II data for duvakitug in ulcerative colitis and Crohn’s disease, showing durable efficacy and a favorable safety profile. These results support a rapid move to phase III trials for the potential TL1A antibody. This pipeline update is significant for Teva, reinforcing its branded pipeline alongside its generics business and contributing to its long-term growth story.
Signet Financial Management LLC Cuts Stake in AbbVie Inc. $ABBV
Signet Financial Management LLC reduced its stake in AbbVie Inc. by 39.2% in the third quarter, selling 16,186 shares and holding 25,094 shares valued at $5.81 million. Despite this, other institutional investors either bought new positions or adjusted their holdings. AbbVie (NYSE:ABBV) currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $251.56, and recently reported strong quarterly earnings and revenue exceeding expectations.
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
Artiva Biotherapeutics announced the appointment of Elaine Sorg to its Board of Directors. Sorg brings over 35 years of biopharmaceutical executive leadership and commercial experience, including the commercialization of major immunology therapies. Her expertise is expected to be invaluable as Artiva prepares to share clinical data for its AlloNK regimen in rheumatoid arthritis and plans for future commercialization.
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
Artiva Biotherapeutics, a clinical-stage biotechnology company, announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings over 35 years of executive leadership and commercial experience in the biopharmaceutical industry, including leading the commercialization of major immunology therapies like HUMIRA and RINVOQ. Her expertise will be invaluable as Artiva prepares to share clinical activity data for its AlloNK regimen in rheumatoid arthritis and engage with the FDA on a registrational trial.
Evercore notes AbbVie Inc.’s (ABBV) Tremfya gains market share, but future earnings growth may be limited
Evercore analysts observed that AbbVie's Tremfya has been gaining market share, surpassing Humira and Enbrel in dermatology. However, despite this positive trend, the firm believes that AbbVie's future earnings growth may be limited. This is attributed to the fact that Tremfya's growth alone might not be enough to fully offset the anticipated decline from Humira's loss of exclusivity.
Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited
Evercore ISI has lowered its price target for AbbVie (ABBV) to $228 from $232, while maintaining an Outperform rating. The firm acknowledges that Tremfya is gaining market share and that AbbVie's 2026 and 2027 guidance seems achievable. However, Evercore notes that buy-side projections have consistently exceeded consensus, suggesting future earnings growth might be limited, and investor focus is shifting to growth beyond 2028 due to anticipated rival treatments.
Evercore Notes AbbVie Inc.'s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited
Evercore ISI has lowered its price target for AbbVie (ABBV) to $228 but maintains an Outperform rating, noting that while Tremfya is gaining market share, future earnings growth might be limited as buy-side projections have surpassed consensus. Investors are increasingly concerned about AbbVie's growth trajectory post-2028 due to anticipated competition, despite the company reporting strong 2025 performance, expanding its pipeline, and expecting significant revenue increases in 2026 driven by Skyrizi and Rinvoq.
Waycross Partners LLC Purchases 8,077 Shares of AbbVie Inc. $ABBV
Waycross Partners LLC increased its stake in AbbVie Inc. (NYSE:ABBV) by 4.8% during the third quarter, acquiring an additional 8,077 shares to hold a total of 177,413 shares valued at approximately $41.08 million. AbbVie recently reported strong Q4 earnings, beating analyst estimates with $2.71 EPS against $2.65 and revenue of $16.62 billion, a 10% year-over-year increase, and provided optimistic guidance for FY 2026. Analysts maintain a "Moderate Buy" rating for AbbVie, with an average price target of $251.56, reflecting confidence in its performance.
Ingalls & Snyder LLC Increases Stock Position in AbbVie Inc. $ABBV
Ingalls & Snyder LLC increased its stake in AbbVie Inc. by 5.8% in the third quarter of 2025, bringing its total holdings to 145,027 shares valued at $33.58 million. This makes AbbVie the 17th largest position in their portfolio, accounting for 1.1% of their investments. AbbVie recently reported strong Q4 earnings, beating analyst estimates, and has an average analyst rating of "Moderate Buy" with a target price of $251.56.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
The iShares U.S. Healthcare ETF (IYH) is a passively managed fund offering broad exposure to the U.S. healthcare sector with a 0.38% expense ratio. While it holds a Zacks ETF Rank of 3 (Hold), it features high-profile holdings like Eli Lilly and Johnson & Johnson, serving as a diversified option for long-term investors.
Top Analyst Reports for AbbVie, RTX & IBM
Zacks Research Daily has published new research reports on 16 major stocks, including AbbVie (ABBV), RTX Corp. (RTX), and International Business Machines Corp. (IBM), along with two micro-cap stocks, EVI Industries (EVI) and Rocky Mountain Chocolate Factory (RMCF). The reports highlight company performance, growth drivers, and potential headwinds for each stock, offering insights for investors.
10 Health Care Stocks With Whale Alerts In Today's Session
This article highlights unusual options activity, known as "whale alerts," for ten health care stocks: AbbVie (ABBV), Abbott Laboratories (ABT), Amgen (AMGN), McKesson (MCK), Madrigal Pharmaceuticals (MDGL), Molina Healthcare (MOH), Merck & Co (MRK), Intellia Therapeutics (NTLA), UnitedHealth Group (UNH), and Vertex Pharmaceuticals (VRTX). It details specific call and put option trades, including strike prices, expiration dates, sentiment, and trade volumes, to help traders identify potential opportunities. The report explains key options terminology for better understanding of these alerts.
Landmark eye trial: two-thirds on AXPAXLI kept vision at 1 year
Ocular Therapeutix reported positive topline results for its AXPAXLI (OTX-TKI) in the SOL-1 Phase 3 superiority trial for wet AMD. The trial successfully met its FDA-aligned primary endpoint at Week 36, demonstrating that 74.1% of subjects maintained vision, and showed durable Week 52 outcomes with 65.9% maintaining vision, surpassing aflibercept. Despite these strong clinical results, the market reacted negatively, with Ocular Therapeutix (NASDAQ: OCUL) stock declining by 21.28% on the news day.
Mubadala Investment Co PJSC reports share stake in Pfizer, AbbVie, dissolves in Merck, Dell
Mubadala Investment Co PJSC has reported changes in its investment portfolio, including acquiring stakes in Pfizer and AbbVie. Concurrently, the company has divested its holdings in Merck and Dell. This strategic shift indicates a reallocation of investment focus within the pharmaceutical and technology sectors.
HSBC Adjusts Price Target on AbbVie to $275 From $265, Maintains Buy Rating
HSBC has increased its price target for AbbVie (ABBV) to $275 from $265, while reiterating a "Buy" rating on the stock. This adjustment reflects a positive outlook from the analytical firm regarding the pharmaceutical company's future performance.
AbbVie Down Since Q4 Earnings Report: How to Play the Stock
Despite beating Q4 earnings and sales estimates, AbbVie's stock experienced downward pressure due to a decline in oncology drug sales and weakness in its aesthetics segment. The company has successfully navigated the patent cliff of Humira with the strong performance of new immunology drugs like Skyrizi and Rinvoq, as well as contributions from its neuroscience and oncology portfolios. While facing challenges such as Humira erosion and a struggling aesthetics segment, AbbVie's robust pipeline, strategic acquisitions, and strong growth expectations for its new drugs suggest continued long-term growth.
Skandinaviska Enskilda Banken AB publ Has $219.56 Million Stock Holdings in AbbVie Inc. $ABBV
Skandinaviska Enskilda Banken AB publ increased its stake in AbbVie Inc. by 7.1% in Q3, now holding 947,375 shares valued at approximately $219.56 million. This makes AbbVie the fund's 18th-largest position, representing 0.9% of its total holdings. Other institutional investors have also adjusted their positions in AbbVie, which recently beat earnings estimates with $2.71 EPS and $16.62 billion in revenue, and currently holds a "Moderate Buy" analyst rating with a consensus target price of $251.00.
Skandinaviska Enskilda Banken AB publ Buys 190,255 Shares of Abbott Laboratories $ABT
Skandinaviska Enskilda Banken AB publ significantly increased its stake in Abbott Laboratories by 51.6%, purchasing 190,255 shares to reach a total of 559,321 shares valued at approximately $74.9 million. This comes as Abbott Laboratories reported quarterly EPS in line with estimates but revenue slightly below expectations, while also increasing its quarterly dividend and seeing insider buying from director Daniel J. Starks. Analysts have a "Moderate Buy" rating on Abbott Laboratories with a consensus price target of $137.05, despite several recent price target reductions.
